RNhale GmbH
Developer of inhalable RNA therapeutics combining RNA interference modalities with dry powder formulation. The company integrates AI-driven lipid nanoparticle (LNP) design with a nano-embedded-microparticle (NEM) dry powder approach to enable room-temperature-stable, scalable pulmonary delivery. Activities include preclinical development toward clinical readiness, process scale-up, and regulatory and market-access planning.
Industries
N/A
Nr. of Employees
small (1-50)
Products
ARISE project – dry powder RNA therapeutic for severe asthma (preclinical)
Preclinical program to develop a dry powder RNA therapeutic for severe asthma using the company's dry powder inhalation platform and formulation technologies. Supported by a European Innovation Council Transition Grant.
ARISE project – dry powder RNA therapeutic for severe asthma (preclinical)
Preclinical program to develop a dry powder RNA therapeutic for severe asthma using the company's dry powder inhalation platform and formulation technologies. Supported by a European Innovation Council Transition Grant.
Services
Development of LNP-based RNA formulations embedded in inhalable microparticles for pulmonary delivery, including AI-enabled formulation design and scale-up considerations.
Development of LNP-based RNA formulations embedded in inhalable microparticles for pulmonary delivery, including AI-enabled formulation design and scale-up considerations.
Expertise Areas
- Pulmonary RNA therapeutics
- RNA interference (RNAi) delivery
- Lipid nanoparticle formulation
- Dry powder inhalation formulation
Key Technologies
- RNA interference (RNAi)
- siRNA and antisense oligonucleotide therapeutics
- Lipid nanoparticles (LNPs)
- Dry powder inhalation
News & Updates
Awarded a €2.5 million European Innovation Council Transition Grant (grant number 101215031) to support development of a dry powder RNA therapeutic for severe asthma and to accelerate preclinical development toward clinical readiness.
Awarded a €2.5 million European Innovation Council Transition Grant (grant number 101215031) to support development of a dry powder RNA therapeutic for severe asthma and to accelerate preclinical development toward clinical readiness.